Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 107,429 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 107,429 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total transaction of $33,302.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, July 6th, Luke Evnin sold 35,770 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.32, for a total value of $11,446.40.
• On Tuesday, June 9th, Luke Evnin sold 76,928 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $28,463.36.
• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total transaction of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total value of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.44, for a total value of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.

Werewolf Therapeutics Trading Up 4.6%

Shares of NASDAQ:HOWL opened at $0.36 on Thursday. Werewolf Therapeutics, Inc. has a 12-month low of $0.27 and a 12-month high of $2.38. The business’s fifty day simple moving average is $0.45 and its 200-day simple moving average is $0.63. The company has a market capitalization of $17.49 million, a PE ratio of -0.29 and a beta of 0.30.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. Research analysts predict that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Regal Investment Advisors LLC grew its holdings in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after buying an additional 221,766 shares during the last quarter. Susquehanna International Group LLP increased its stake in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics in the 3rd quarter worth $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

HOWL has been the topic of several analyst reports. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings lowered Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Werewolf Therapeutics has a consensus rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.